Purchase of Salix adds gastrointestinal drugs to Valeant stable
Valeant will pay US$158 a share in cash for Salix in US$10.1 billion acquisition
New York
VALEANT Pharmaceuticals International Inc agreed to buy Salix Pharmaceuticals Ltd for about US$10.1 billion, a person with knowledge of the matter said, to add gastrointestinal drugs to its stable of offerings.
Valeant will pay US$158 a share in cash for Salix, the person said, asking not to be identified because the company hasn't announced the deal. Salix shares rose US$7.11 to US$157.85 last Friday, almost completely eliminating any premium in the purchase price.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
UBS weighs synthetic risk transfer amid capital boost proposals
Oil settles higher on supply concerns in the Mid-East, economic woes subdue gains
S-Reits falter as investors weigh possibility of zero rate cuts in 2024
CapitaLand Investment posts total revenue of S$650 million for Q1
Europe: Stoxx 600 logs best day in three months as banks shine
US: Stocks rally after strong tech results